Patients presenting with acute coronary syndrome (ACS) or non-ACS who were on clopidogrel monotherapy after 6-18 months of event-free dual antiplatelet therapy (DAPT) post-percutaneous coronary intervention (PCI) and without any ischemic and major bleeding events had more long-term clinical benefit than patients on post-DAPT aspirin monotherapy, a new subgroup analysis of the HOST-EXAM study shows.